Table 1.

Baseline demographics of all patients who started treatment with simeprevir plus sofosbuvir with or without ribavirin

Characteristic	SOF SMV (n=667)	SOF SMV RBV (n=169)	Total (n=836)
Mean age (range), years	59 (20–83)	59 (29–80)	59 (20–83)
18–39	23 (3.4)	6 (3.6)	29 (3.5)
40–64	470 (70.5)	133 (78.7%)	603 (72.1)
65+	174 (26.1)	30 (17.8)	204 (24.4)
Male sex, n (%)	405 (60.7)	104 (61.5)	509 (60.9)
Race, n (%)
White	504 (75.6)	134 (79.3)	638 (76.3)
Black	88 (13.2)	24 (14.2)	112 (13.4)
Asian	13 (1.9)	1 (0.6)	14 (1.7)
Other/missing	62 (9)	10 (6)	72 (9)
Hispanic ethnicity, n (%)	31 (4.6)	11 (6.5)	42 (5.0)
Mean ALT (range), IU/l	80 (8.0–409)	86 (12.0–337)	81 (8.0–409)
Mean total bilirubin (range) mg/dl	1.0 (0.1–8.0)	1.2 (0.2–10.7)	1.1 (0.1–10.7)
Mean albumin (range), g/dl	3.8 (1.2–5.3)	3.8 (1.8–4.7)	3.8 (1.2–5.3)
Mean hemoglobin (range), g/dl	14.0 (7.3–18.8)	14.1 (9.7–18.6)	14.0 (7.3–18.8)
Mean platelet count (range) (×103) per µl	152 (24.0–595)	137 (24.0–521)	149 (24.0–595)
History of cirrhosis, n (%)	381 (57.1)	110 (65.1)	491 (58.7)
History of liver decompensation (among cirrhotics), n (%)	168 (44.1)	53 (48.2)	221 (45.0)
MELD among cirrhotics
0–9	162 (42.5)	47 (42.7)	209 (42.6)
10–15	101 (26.5)	21 (19.1)	122 (24.8)
16–21	10 (2.6)	3 (2.7)	13 (2.6)
21–39	5 (1.3)	1 (0.9)	6 (1.2)
Pending	103 (27.0)	38 (34.5)	141 (28.7)
Presence of diabetes, n (%)	147 (22.0)	46 (27.2)	193 (23.1)
HCV genotype, n (%)
1a	381 (57.1)	128 (75.7)	509 (60.9)
1b	221 (33.1)	21 (12.4)	242 (28.9)
1, subtype unspecified	65 (9.7)	20 (11.8)	85 (10.2)
Q80K mutation tested	67 (10.0)	23 (13.6)	90 (10.7)
Q80K mutation present	28 (4.2)	14 (8.3)	42 (5.0)
Prior HCV treatment, n (%)
Treatment naïve	263 (39.4)	63 (37.3)	326 (39.0)
Prior Peg/Rbv treatment failures	317 (47.5)	70 (41.4)	387 (46.3)
Prior telaprevir or boceprevir treatment failure	66 (9.9)	34 (20.1)	100 (12.0)